Segment Reporting (Tables)

3 Months Ended

Jun. 02, 2018

Schedule of balance sheet information for the Company's reportable segments

	Retail Pharmacy		Pharmacy Services		Eliminations(2)			Consolidated
June 2, 2018:
Total Assets	$	5,434,447	$	2,950,099	$	(55,093	)	$	8,329,453
Goodwill	43,493		1,377,627		—			1,421,120
Additions to property and equipment and intangible assets	58,067		3,559		—			61,626
March 3, 2018:
Total Assets	$	6,089,343	$	2,954,953	$	(54,969	)	$	8,989,327
Goodwill	43,492		1,377,628		—			1,421,120
Additions to property and equipment and intangible assets	199,437		15,327		—			214,764

(2)As of June 2, 2018 and March 3, 2018, intersegment eliminations include netting of the Pharmacy Services segment long-term deferred tax liability of $40,319 and $38,713, respectively, against the Retail Pharmacy segment long-term deferred tax asset for consolidation purposes in accordance with ASC 740, and intersegment accounts receivable of $14,774 and $16,256, respectively, that represents amounts owed from the Pharmacy Services segment to the Retail Pharmacy segment that are created when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products.

Schedule of reconciliation of the Company's business segments to the condensed consolidated financial statements

	Retail Pharmacy		Pharmacy Services		Intersegment Eliminations(1)			Consolidated
June 2, 2018:
Revenues	$	3,897,765	$	1,542,762	$	(52,037	)	$	5,388,490
Gross Profit	1,069,457		99,292		—			1,168,749
Adjusted EBITDA(2)	113,469		33,863		—			147,332
June 3, 2017:
Revenues	$	3,972,351	$	1,513,241	$	(49,069	)	$	5,436,523
Gross Profit	1,056,971		104,972		—			1,161,943
Adjusted EBITDA(2)	87,365		48,599		—			135,964

(1)

Intersegment eliminations include intersegment revenues and corresponding cost of revenues that occur when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products. When this occurs, both the Retail Pharmacy and Pharmacy Services segments record the revenue on a stand-alone basis.

(2)

See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” in MD&A for additional details. The following is a reconciliation of net (loss) income to Adjusted EBITDA for the thirteen week periods ended June 2, 2018 and June 3, 2017:

Schedule of reconciliation of net income to Adjusted EBITDA

	June 2, 2018 (13 weeks)			June 3, 2017 (13 weeks)
Net loss from continuing operations	$	(41,727	)	$	(36,037	)
Interest expense	62,792			51,000
Income tax benefit	(9,497		)	(12,121		)
Depreciation and amortization expense	94,529			101,029
LIFO charge	9,966			10,173
Lease termination and impairment charges	9,859			4,038
Loss on debt retirements, net	554			—
Other	20,856			17,882

Adjusted EBITDA from continuing operations	$	147,332		$	135,964